Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about AZN, unsubscribe in one click. Privacy
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Benralizumab FDA approved Nov 2017 · Fasenra |
Asthma | Phase 4 · NCT03953300 | Completed |
| Rosuvastatin FDA approved Aug 2003 · Crestor |
Hypercholesterolemia | Phase 3 · NCT07930507 | Not yet recruiting |
| Olaparib FDA approved Dec 2014 · Lynparza (discontinued) |
Relapsed Ovarian Cancer | Phase 3 · NCT03534453 | Completed |
| Acalabrutinib FDA approved Oct 2017 · Calquence |
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Phase 3 · NCT05057494 | Active not recruiting |
| Anifrolumab FDA approved Jul 2021 · Saphnelo |
Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus… | Phase 3 · NCT07691970 | Recruiting |
| Selumetinib FDA approved Apr 2020 · Koselugo |
Neurofibromatosis 1 | Phase 3 · NCT04924608 | Active not recruiting |
| Tezepelumab FDA approved Dec 2021 · Tezspire |
Asthma | Phase 3 · NCT06023589 | Recruiting |
| Durvalumab FDA approved May 2017 · Imfinzi |
Triple Negative Breast Neoplasms | Phase 1/2 · NCT03742102 | Active not recruiting |
| Capivasertib FDA approved Nov 2023 · Truqap |
Triple Negative Breast Neoplasms | Phase 1/2 · NCT03742102 | Active not recruiting |
| Benralizumab Prefilled Syringe | Asthma; Eosinophilic | Phase 4 · NCT04565483 | Completed |
| FDC laroprovstat/Rosuvastatin 2 | Hypercholesterolemia | Phase 3 · NCT07930507 | Not yet recruiting |
| Rosuvastatin 2 | Dyslipidaemia | Phase 2/3 · NCT06834932 | Active not recruiting |
| Rosuvastatin 1 | Dyslipidaemia | Phase 2/3 · NCT06834932 | Active not recruiting |
| Endocrine therapy | Advanced Breast Cancer | Phase 3 · NCT07683754 | Recruiting |
| FDC laroprovstat/Rosuvastatin 1 | Hypercholesterolemia | Phase 3 · NCT07930507 | Not yet recruiting |
| Laroprovstat | Hypercholesterolemia | Phase 3 · NCT07930507 | Not yet recruiting |
Also used in these trials (approved or third-party drugs, not AZN's own candidates): Clopidogrel Bisulfate, Docetaxel Anhydrous, Carboplatin, Rivaroxaban, Obinutuzumab, Paclitaxel, Palbociclib, Pembrolizumab, Pertuzumab, Venetoclax, Trastuzumab, Adjuvant durvalumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
AZN holds $8.2B in cash and short-term investments and its operations are currently cash-flow neutral or positive.
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AZN files for a raise →
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-11-06 filed 2026-11-10 |
Sharma Mani |
Award (A) | 1 | $186.24 | 19,292 |
| 2026-10-06 filed 2026-10-08 |
Sharma Mani |
Award (A) | 2 | $159.80 | 19,291 |
| 2026-09-08 filed 2026-09-11 |
Sharma Mani |
Award (A) | 1 | $162.60 | 19,289 |
| 2026-08-08 filed 2026-09-11 |
Sharma Mani |
Purchase (P) | 20 | $160.57 | 19,288 |
| 2026-08-06 filed 2026-08-07 |
Sharma Mani |
Award (A) | 2 | $163.34 | 19,267 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AZN and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →